Asset
Cabozantinib S-malate
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01100619 | phase1 | completed | 2010-04-01 | 2012-08-01 | Exelixis | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors |
| NCT00596648 | phase1_2 | completed | 2008-02-12 | 2012-08-02 | Exelixis | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
| NCT00704730 | phase3 | completed | 2008-06-01 | 2011-10-01 | Exelixis | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer |
| NCT00960492 | phase1 | completed | 2009-09-01 | 2012-11-01 | Exelixis | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma |
| NCT00215605 | phase1 | completed | 2005-09-01 | 2011-04-01 | Exelixis | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 203756 | NDA | EXELIXIS INC |
| NDA 208692 | NDA | EXELIXIS INC |
Marketed products (5)
- CABOMETYX
- CABOMETYX
- CABOMETYX
- COMETRIQ
- COMETRIQ